Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases in the United States. The company's lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. It also provides ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. Anavex Life Sciences Corp. was incorporated in 2001 and is headquartered in New York, New York.

Period	Debt/Equity
2016-09-30	0.51
2017-09-30	0.15
2018-09-30	0.18
2019-09-30	0.25
2020-09-30	0.27
2021-09-30	0.07
2022-09-30	0.07
2023-09-30	0.09
2024-09-30	0.13
2025-09-30	0.09

	A	B	C	D
1	Symbol	Price	Change	Volume
2	AVXL	$3.06	-0.49%	0.72M
3
4
5

Anavex Life Sciences Corp. (AVXL) Debt to Equity Ratio

Debt to Equity Ratio Data

Get Anavex Life Sciences Corp. Data in Excel

More AVXL Financial Data